FIELD: medicine.
SUBSTANCE: Irinotecan, Cisplatin and Aranose are introduced sequentially in doses making 1/4 of maximum tolerated every 10-20 minutes in two-fold or three-fold administration regimen.
EFFECT: method provides antitumourigenesis ensured by combined effect of the preparations and improved therapy tolerance.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
| METHOD OF TREATING LUNG CANCER | 2009 |
|
RU2414894C1 |
| INHIBITORS OF CELL CYCLE CHECKPOINT KINASE 1 FOR AMPLIFICATION OF DNA-DAMAGING AGENTS | 2010 |
|
RU2567044C2 |
| METHOD OF TREATING COLON CANCER | 2012 |
|
RU2529831C2 |
| METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
| METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
| COMBINATION OF DEHYDROXYMETHYL EPOXYQUINOMYCIN (DHMEQ) AND CYTOSTATICS FOR TREATING OVARIAN CANCER | 2018 |
|
RU2704020C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING NANOPARTICLES CONTAINING INSOLUBLE COMPOUND BASED ON CAMPTOTHECIN FOR TREATING CANCER, AND COMBINATION THERAPY USING THEREOF | 2021 |
|
RU2827894C1 |
| AGENT INTENSIFYING ACTION OF ANTI-CANCER AGENTS | 2012 |
|
RU2589713C2 |
| ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
